[Neuprotection of post-acute COVID-19 cognitive impairment].

Objective: To evaluate the efficacy of Cortexin in the treatment of patients with post-Covid impairment.

Material And Methods: Treatment results of 109 patients with post-Covid cognitive impairment aged from 42 to 65 years were analyzed. The main group (MG, =52), 29 (55.8%) men and 23 (44.2%) women, average age 58.1±4.9 years, who received Cortexin continuously for 20 days at a dose of 10 mg i.m., after 3, 6 months. The comparison group included 57 people, 31 (54.4%) men and 26 (45.6%) women (average age 59.3±3.8 years). The effectiveness of therapy was assessed using neuropsychological testing with international scales.

Results: During treatment, statistically significant differences were obtained in MG patients in the form of improved concentration (<0.05), increased control of exutative functions (<0.05), and auditory-verbal memory (=0.002). There were no adverse events in the MG.

Conclusion: Cortexin is highly effective and safe, and can be recommended as part of a combined staged therapy for post-Covid cognitive impairment. Thus, the study confirms the feasibility of using Cortexin, which has a neurocytoprotective effect.